midbrain, left frontal lobe, insular cortex, and medial temporal lobe. Cerebrospinal fluid (CSF) study was within normal limits (protein of 23 mg/dL; cell count of 4 lymphocytes/dL; sugar of 69 mg/dL; ADA: 14 U/L; India ink negative; Gram stain negative). HIV and HbSAg tests were negative. ANA screening was negative. The patient was treated with oral prednisolone, levetiracetam, and supportive measures and improved.
The patient was readmitted after 2 months with dysphagia and nasal regurgitation after she had discontinued oral steroids. Repeat MRI showed persistent signal changes in the left side of midbrain and pons, newly appeared subtle signal changes in medulla around the central canal, gliotic changes in the left frontal lobe, insular cortex and medial temporal lobe, and no focal-enhancing lesions. Her symptoms improved after restarting steroids. She was taking oral prednisolone 10 mg/day which she had again discontinued 3 months before the present admission.
Based on the history and examination findings, differential diagnosis of relapsing-remitting demyelinating illness, recurrent ADEM, and vasculitis were considered.
Routine hematological and biochemical investigations were within normal limits. MRI of the brain and whole spine was done. There were hyperintense signal changes on T2 and FLAIR sequences in hypothalamus, periaqueductal gray, and pontine tegmentum [ Figure 1a -c]. There was hypointensity on T1 imaging in the left cerebral peduncle suggestive of previous insult. Whole spine MRI showed T2 hyperintense lesion at D10 vertebral level [ Figure 1d ].
Serum NMO antibody test (by immunofluorescence method) was done, and the result was positive.
The patient improved symptomatically after starting steroids. Her sleep duration reduced from 22 h to 16 h during hospital stay, and diplopia and ataxia were improved. She was started on azathioprine along with oral steroids and was discharged.
dIscussIon
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness. Primary narcolepsy is caused by selective loss of hypocretin-1-producing neurons. An autoimmune process is thought to be the likely cause as certain human leukocyte antigens (HLAs) that increase the risk of autoimmune disorders are strongly associated with primary narcolepsy. HLA DQB1*0602 is found in more than 85% of people with primary narcolepsy. [5] Symptomatic narcolepsy occurs rarely with neurologic disorders such as tumor, stroke, or demyelinating disorders that directly damage hypocretin-1-producing neurons in the hypothalamus. [6] Narcolepsy has been reported in autoimmune demyelinating disorders, MS and NMO.
Our patient had narcolepsy as the presenting symptom with signal changes in hypothalamus on MRI. Her previous symptoms of hemiparesis and dysphagia could be part of symptomatic cerebral syndrome and acute brainstem syndrome of NMO. However, anti-aquaporin-4 antibody test was not done at that time as diagnosis of NMO was not considered at that stage.
Kanbayashi et al. reported 7 cases of excessive daytime sleepiness with symmetrical inflammatory hypothalamic lesions, of which 3 patients were anti-aquaporin-4 antibody positive. CSF hypocretin-1 levels in all the patients were significantly reduced. Aquaporin 4 is expressed in astrocytes, predominantly in periaqueductal and periventricular regions. An immune attack on aquaporin 4 in periventricular regions in the hypothalamus may secondarily affect the hypocretin neurons. [7] Carlander et al. reported a case of NMO who was anti-aquaporin-4 antibody positive and had associated excessive daytime sleepiness and hypocretin deficiency. [8] Poppe et al. reported two additional NMO cases presenting with excessive daytime sleepiness with symmetrical hypothalamic lesions although anti-aquaporin-4 antibody titer was not measured in these cases. [9] Traditionally, NMO was considered as a disease of spinal cord and optic nerves. The discovery of aquaporin-4 IgG antibodies specific for NMO has broadened the clinical and neuroimaging spectrum of NMO with increasing recognition of nonopticospinal forms. This lead to introduction of the term NMO spectrum disorders in 2007. [10] Further advances have rendered the 2006 criteria inadequate leading to the revised international consensus diagnostic criteria in 2015. [4] Symptomatic narcolepsy is one of the core clinical characteristics in the revised diagnostic criteria. 
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